The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review

Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension. We reviewed published data on the effects of phosphodiesterase-5 inhibitors on CBF in adult humans. A systematic review according to PRISMA guidelines was performed. Embase, Medline and Cochrane Library Trials databases were searched. Sixteen studies with 353 participants in total were retrieved. Studies included healthy volunteers and patients with migraine, ED, type 2 diabetes, stroke, pulmonary hypertension, Becker muscular dystrophy and subarachnoid haemorrhage. Most studies used middle cerebral artery flow velocity to estimate CBF. Few studies employed direct measurements of tissue perfusion. Resting CBF velocity was unaffected by phosphodiesterase-5 inhibitors, but cerebrovascular regulation was improved in ED, pulmonary hypertension, diabetes, Becker's and a group of healthy volunteers. This evidence suggests that phosphodiesterase-5 inhibitors improve responsiveness of the cerebral vasculature, particularly in disease states associated with an impaired endothelial dilatory response. This supports the potential therapeutic use of phosphodiesterase-5 inhibitors in vascular cognitive impairment where CBF is reduced. Further studies with better resolution of deep CBF are warranted. The review is registered on the PROSPERO database (registration number CRD42016029668).

[1]  Sandra E. Black,et al.  Vascular cognitive impairment , 2018, Nature Reviews Disease Primers.

[2]  A. Hainsworth,et al.  Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies. , 2017, Cellular signalling.

[3]  E. Rostrup,et al.  Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS): study protocol for a randomised controlled trial , 2017, Trials.

[4]  Thalia Shoshana Field,et al.  Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment , 2017, Journal of the American Heart Association.

[5]  G. Jacob,et al.  Nitric oxide-sensitive guanylyl cyclase signaling affects CO2-dependent but not pressure-dependent regulation of cerebral blood flow. , 2017, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  M. Moss,et al.  Translational models for vascular cognitive impairment: a review including larger species , 2017, BMC Medicine.

[7]  Ian Marshall,et al.  Cerebral blood flow in small vessel disease: A systematic review and meta-analysis , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  AS Elhwuegi The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History , 2016, Annals of medical and health sciences research.

[9]  C. Derdeyn,et al.  Acute Effect of Intravenous Sildenafil on Cerebral Blood Flow in Patients with Vasospasm After Subarachnoid Hemorrhage , 2016, Neurocritical Care.

[10]  Ian Marshall,et al.  Magnetic resonance imaging for assessment of cerebrovascular reactivity in cerebral small vessel disease: A systematic review , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  M. Chicoine,et al.  A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage. , 2016, Journal of neurosurgery.

[12]  H. Markus,et al.  Application of Diffusion Tensor Imaging Parameters to Detect Change in Longitudinal Studies in Cerebral Small Vessel Disease , 2016, PloS one.

[13]  E. Rostrup,et al.  Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy , 2016, Neurotherapeutics.

[14]  E. Achten,et al.  A neuroradiologist’s guide to arterial spin labeling MRI in clinical practice , 2015, Neuroradiology.

[15]  H. Markus,et al.  Pattern and Rate of Cognitive Decline in Cerebral Small Vessel Disease: A Prospective Study , 2015, PloS one.

[16]  H. Markus,et al.  The Brief Memory and Executive Test (BMET) for detecting vascular cognitive impairment in small vessel disease: a validation study , 2015, BMC Medicine.

[17]  L. Bridges,et al.  Endothelial Cells and Human Cerebral Small Vessel Disease , 2015, Brain pathology.

[18]  Y. Lampl,et al.  Regional cerebral blood flow following single‐dose and continuous‐dose tadalafil after stroke , 2014, Acta neurologica Scandinavica.

[19]  David C. Anderson,et al.  Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial , 2014, The Lancet Neurology.

[20]  M. Esiri,et al.  PHOSPHODIESTERASE 5 (PDE5) AS A POTENTIAL THERAPEUTIC TARGET IN SMALL ARTERIES OF AGED HUMAN BRAINS , 2014, Alzheimer's & Dementia.

[21]  M. Nelson,et al.  Neurovascular signaling in the brain and the pathological consequences of hypertension. , 2014, American journal of physiology. Heart and circulatory physiology.

[22]  Thomas M. Sanderson,et al.  The role of phosphodiesterases in hippocampal synaptic plasticity , 2013, Neuropharmacology.

[23]  E. Vicaut,et al.  Cerebral and Extracerebral Vasoreactivity in Symptomatic Lacunar Stroke Patients: A Case-Control Study , 2013, International journal of stroke : official journal of the International Stroke Society.

[24]  M. Dichgans,et al.  Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging , 2013, The Lancet Neurology.

[25]  J. Lanciego,et al.  Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD , 2013, Neuropharmacology.

[26]  M. Chopp,et al.  Sildenafil Enhances Neurogenesis and Oligodendrogenesis in Ischemic Brain of Middle-Aged Mouse , 2012, PloS one.

[27]  Wilhelm Kuker,et al.  Increased Cerebral Arterial Pulsatility in Patients With Leukoaraiosis: Arterial Stiffness Enhances Transmission of Aortic Pulsatility , 2012, Stroke.

[28]  W. M. van der Flier,et al.  White Matter Lesion Progression in LADIS: Frequency, Clinical Effects, and Sample Size Calculations , 2012, Stroke.

[29]  Marc Fisher,et al.  Identifying and utilizing the ischemic penumbra , 2012, Neurology.

[30]  M. Reinhard,et al.  Cerebral autoregulation in acute ischemic stroke , 2012 .

[31]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[32]  F. Al-amran,et al.  Autonomic cerebral vascular response to sildenafil in diabetic patient , 2012, Diabetology & Metabolic Syndrome.

[33]  S. Singh,et al.  Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study , 2012, Surgical neurology international.

[34]  A. Cocchiarella Partial motor restoration upon administration of sildenafil: a case study , 2012, Developmental neurorehabilitation.

[35]  Charles DeCarli,et al.  White matter hyperintensities and cognition: Testing the reserve hypothesis , 2011, Neurobiology of Aging.

[36]  A. Lee,et al.  Vascular Dementia , 2011, Chonnam medical journal.

[37]  E. Karran,et al.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues , 2010, Neuropharmacology.

[38]  L. Pantoni Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges , 2010, The Lancet Neurology.

[39]  Kirsten Shuler,et al.  A Systematic Review of Dynamic Cerebral and Peripheral Endothelial Function in Lacunar Stroke Versus Controls , 2010, Stroke.

[40]  I. Mena,et al.  The effect of sildenafil citrate (Viagra) on cerebral blood flow in patients with cerebrovascular risk factors , 2009, Acta neurologica Scandinavica.

[41]  P. Stoeter,et al.  Sildenafil improves scotoma after posterior cerebral infarctions: a case report , 2010, Journal of Neurology.

[42]  S. Finklestein,et al.  Phosphodiesterase 5A Inhibitors Improve Functional Recovery after Stroke in Rats: Optimized Dosing Regimen with Implications for Mechanism , 2009, Journal of Pharmacology and Experimental Therapeutics.

[43]  Norbert Schuff,et al.  Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging , 2009, Alzheimer's & Dementia.

[44]  Frederik Barkhof,et al.  Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort , 2009, BMJ : British Medical Journal.

[45]  A. Palmeri,et al.  Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-β Load in an Alzheimer's Disease Mouse Model , 2009, The Journal of Neuroscience.

[46]  E. Rostrup,et al.  Cerebral Haemodynamic Response or Excitability is not Affected by Sildenafil , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  P. Kelly,et al.  Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats , 2009, Neuropsychopharmacology.

[48]  T. Brown,et al.  Regression algorithm correcting for partial volume effects in arterial spin labeling MRI , 2008, Magnetic resonance in medicine.

[49]  L. Pantoni,et al.  The relation between white-matter lesions and cognition , 2007, Current opinion in neurology.

[50]  G. Mensah,et al.  Vascular endothelium summary statement I: Health promotion and chronic disease prevention. , 2007, Vascular pharmacology.

[51]  R. Tuder,et al.  Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.

[52]  H. Markus,et al.  Asymmetric Dimethylarginine in Cerebral Small Vessel Disease , 2007, Stroke.

[53]  K. Jellinger,et al.  The enigma of vascular cognitive disorder and vascular dementia , 2007, Acta Neuropathologica.

[54]  Donald H. Lee,et al.  Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. , 2006, Stroke.

[55]  S. Brenner Sildenafil increases cerebrovascular reactivity: A transcranial Doppler study , 2006, Neurology.

[56]  W. Seeger,et al.  Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension , 2006, Cerebrovascular Diseases.

[57]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[58]  J. Olesen,et al.  Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. , 2005, European journal of pharmacology.

[59]  Arthur R. Bradwell,et al.  Effect of sildenafil and acclimatization on cerebral oxygenation at altitude. , 2005, Clinical science.

[60]  H. Nukui,et al.  Phosphodiesterase 5 inhibitor, zaprinast, selectively increases cerebral blood flow in the ischemic penumbra in the rat brain , 2005, Neurological research.

[61]  J. Wharton,et al.  Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.

[62]  A. Hofman,et al.  Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study , 2005, Annals of neurology.

[63]  Jean-Jacques Moraine,et al.  Effects of High Altitude Exposure on Cerebral Hemodynamics in Normal Subjects , 2005, Stroke.

[64]  E. Fiumana,et al.  Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells , 2005, Basic Research in Cardiology.

[65]  J. Corbin,et al.  Mechanisms of action of PDE5 inhibition in erectile dysfunction , 2004, International Journal of Impotence Research.

[66]  C. Iadecola Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[67]  T. H. Klotz,et al.  Sildenafil (Viagra®): Is there an influence on psychological performance? , 2004, International Urology and Nephrology.

[68]  M. F. Goy,et al.  mRNA expression patterns of the cGMP‐hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain , 2003, The Journal of comparative neurology.

[69]  Marc Fisher,et al.  The Ischemic Penumbra: Identification, Evolution and Treatment Concepts , 2003, Cerebrovascular Diseases.

[70]  F. Hofmann,et al.  Individual Cerebellar Purkinje Cells Express Different cGMP Phosphodiesterases (PDEs): In Vivo Phosphorylation of cGMP-Specific PDE (PDE5) as an Indicator of cGMP-dependent protein kinase (PKG) Activation , 2003, The Journal of Neuroscience.

[71]  K. Weissenborn,et al.  Effect of sildenafil (Viagra®) on cerebral blood flow velocity: a pilot study , 2003, Psychiatry Research: Neuroimaging.

[72]  Hugh S Markus,et al.  Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. , 2003, Brain : a journal of neurology.

[73]  J. Olesen,et al.  Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. , 2003, Brain : a journal of neurology.

[74]  A. Quyyumi,et al.  The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. , 2002, Journal of the American College of Cardiology.

[75]  N. Pereira,et al.  Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. , 2002, The American journal of cardiology.

[76]  J. Olesen,et al.  The Phosphodiesterase 5 Inhibitor Sildenafil Has No Effect on Cerebral Blood Flow or Blood Velocity, but Nevertheless Induces Headache in Healthy Subjects , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[77]  E Rostrup,et al.  Cerebral Perfusion and Cerebrovascular Reactivity Are Reduced in White Matter Hyperintensities , 2002, Stroke.

[78]  C. Stein,et al.  The effect of sildenafil on nitric oxide–mediated vasodilation in healthy men , 2001, Clinical pharmacology and therapeutics.

[79]  N. Morrell,et al.  Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension , 2001, Circulation.

[80]  J. Olesen,et al.  The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. , 2001, European journal of pharmacology.

[81]  T. Münte,et al.  Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials , 2001, World Journal of Urology.

[82]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[83]  H S Markus,et al.  Reduced cerebral blood flow in white matter in ischaemic leukoaraiosis demonstrated using quantitative exogenous contrast based perfusion MRI , 2000, Journal of neurology, neurosurgery, and psychiatry.

[84]  T. Kitazono,et al.  Role of potassium channels in cerebral blood vessels. , 1995, Stroke.

[85]  D. Newell,et al.  Comparison of static and dynamic cerebral autoregulation measurements. , 1995, Stroke.

[86]  M. Nelson,et al.  Physiological roles and properties of potassium channels in arterial smooth muscle. , 1995, The American journal of physiology.

[87]  K. Hossmann Viability thresholds and the penumbra of focal ischemia , 1994, Annals of neurology.

[88]  H. Markus,et al.  Estimation of Cerebrovascular Reactivity Using Transcranial Doppler, Including the Use of Breath‐Holding as the Vasodilatory Stimulus , 1992, Stroke.